Lyell Immunopharma (LYEL) EBITDA Margin (2020 - 2026)
Lyell Immunopharma's EBITDA Margin came in at -1127875.00% for Q2 2026, down 577812.50 percentage points from -550062.50% a year earlier but up 968575.00 percentage points from the prior quarter.
Lyell Immunopharma (LYEL) EBITDA Margin (2020 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, Lyell Immunopharma reported EBITDA Margin of -914733.33%, down 348271.67 percentage points year-over-year; for FY2025, it came in at -716291.67%, down 160350.68 percentage points from FY2024.
- EBITDA Margin has declined in each of the last three years, with a five-year change of -713614.47 percentage points (FY2020 to FY2025).
- Going back by year, EBITDA Margin was -555940.98% in FY2024 (-381511.75 pp), -174429.23% in FY2023 (-174229.62 pp), -199.61% in FY2022 (+1689.14 pp) and -1888.75% in FY2021 (+788.44 pp).
- The five-year range for quarterly EBITDA Margin is -2096450.00% (Q1 2026) to -20.14% (Q4 2022).
- Year-over-year, EBITDA Margin has declined for five consecutive quarters, with an average year-over-year change of -358090.66 percentage points over the last eight quarters.
- The fastest year-over-year change in EBITDA Margin over five years came in Q3 2023 (a gain of 1844793.33 percentage points), and the weakest in Q3 2022 (a drop of 2058897.40 percentage points).
- Business Quant data shows LYEL's EBITDA Margin at -2096450.00% (Q1 2026), -2087450.00% (Q4 2025) and -231246.67% (Q3 2025) in the three quarters before Q2 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 35.95% |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 49.01% |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 6.02% |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 33.11% |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 46.01% |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | -124.26% |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 39.16% |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 39.10% |
| 10 | Lyell Immunopharma | 227.89 Mn | 227.89 Mn | - | -1,127,875.00% |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,127,875.00% |
| Mar 31, 2026 | -2,096,450.00% |
| Dec 31, 2025 | -2,087,450.00% |
| Sep 30, 2025 | -231,246.67% |
| Jun 30, 2025 | -550,062.50% |
| Mar 31, 2025 | -770,371.43% |
| Dec 31, 2024 | -1,782,918.18% |
| Sep 30, 2024 | -134,779.41% |
| Jun 30, 2024 | -358,669.23% |
| Mar 31, 2024 | -1,685,033.33% |
| Dec 31, 2023 | -418,853.85% |
| Sep 30, 2023 | -215,740.00% |
| Jun 30, 2023 | -225,344.44% |
| Mar 31, 2023 | -88,506.15% |
| Dec 31, 2022 | -20.14% |
| Sep 30, 2022 | -2,060,533.33% |
| Jun 30, 2022 | -92.58% |
| Mar 31, 2022 | -11,643.58% |
| Dec 31, 2021 | -1,522.79% |
| Sep 30, 2021 | -1,635.93% |
Lyell Immunopharma EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=LYEL&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "LYEL", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=LYEL&period=max&api_key=YOUR_API_KEY");
const data = await res.json();